Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link

  • The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL-induced apoptosis in several human cancers. However, the identification of the underlying molecular mechanisms of this synergistic cell death induction has been ongoing over the last years. A recent study identifies a new mechanism of action for the synergism of TRAIL and Bortezomib.

Download full text files

Export metadata

Metadaten
Author:Simone FuldaORCiDGND
URN:urn:nbn:de:hebis:30-102383
URL:http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=277&path[]=421
DOI:https://doi.org/10.18632/oncotarget.277
ISSN:1949-2553
Parent Title (English):Oncotarget
Publisher:Impact Journals LLC
Place of publication:[S.l.]
Document Type:Article
Language:English
Date of Publication (online):2011/05/16
Date of first Publication:2011/05/16
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2011/08/08
Tag:TRAIL; apoptosis; cancer; chemotherapy; proteasome inhibitor
Volume:2
Issue:5
Page Number:4
First Page:418
Last Page:421
Note:
Copyright: © Fulda. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
HeBIS-PPN:272535168
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 3.0